December 14, 2024, New Brunswick, NJ – Vaneltix Pharma, Inc. (“Vaneltix” or “the Company”), a specialty pharmaceutical company focused on the development of solutions for the six million people with pelvic and bladder pain, announced the start of its second clinical trial, the VNX001-110 trial to study the safety, efficacy, and frequency of administration of VNX001 (Alenura®) in the Treatment of IC/BPS. The study gives subjects who completed the VNX001-111 trial an opportunity to receive a course of open label treatment with VNX001to treat a painful flare of IC/BPS for up to 2 weeks, and is also open to subjects who did not enroll in VNX001-111 study at select sites. The VNX001-111 study has also been renamed to include the title Engage 2024 study.
Read more: Engage-24.com
About Vaneltix
Vaneltix Pharma, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products focused on derisked programs that can be developed through the FDA 505(b)(2) regulatory and unabbreviated pathways. Vaneltix’s development programs target significant unmet medical need and major market opportunities in urology and women’s health care. Vaneltix’s lead clinical program is Alenura®, a proprietary combination of the approved drugs lidocaine and heparin that is instilled into the bladder, and targets Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS), an unmet medical need which affects at least 6 million 1 men and women in the US. For further information, please visit Vaneltix’s website at http://www.vaneltix.com.